the 15-year clinical study with Copaxone(R) (glatiramer acetate injection), which is the longest prospective and continuous evaluation ever conducted in relapsing-remitting multiple sclerosis . . .
80 percent of patients were still walking without assistance despite a mean MS disease duration of 22 years, and two-thirds of patients have not transitioned to secondary progressive MS read more »
Helen Yates, Chief Executive of the Multiple Sclerosis Resource Centre (MSRC) said: “We truly hope that the research leads to a treatment for this very worrying and potentially life threatening condition. It is important that people affected by MS that are
In the development of new therapies for multiple sclerosis, there are occasions in which the results of a study surprise investigators and challenge their long-held beliefs about MS. A recent example is the evolving story concerning the development of a drug called rituximab as a treatment for MS, specifically read more »
